Company Research Report: Blue Earth Diagnostics
Company Overview
- Name: Blue Earth Diagnostics
- Mission: To transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
- Founded: 2014
- Founder: Dr. Jonathan Allis
- Headquarters: The Oxford Science Park, Magdalen Centre, Robert Robinson Avenue, Oxford OX4 4GA, UK
- Subsidiary: Bracco Imaging S.p.A.
- Key People:
- Chief Executive Officer: Marco Campione
- Chief Medical Officer: Dr. Eugene Teoh MBBS, MRCP, FRCR, D.Phil.
- Vice President Human Resources: Jonathan Fitzpatrick
- Head of Research & Development: Matthew Miller PhD
- Head of Operations & Supply Chain: Matt Morrison PhD
- VP Quality Assurance: Richard Petherick
- General Counsel & Company Secretary: Chelsea Roche, BSc LLB
- Chief Financial Officer: Andrea Scampoli
- President Blue Earth Diagnostics Inc: Terri Wilson
- Board Members:
- CEO Blue Earth Diagnostics Ltd: Marco Campione
- Chief Executive Officer at Bracco Imaging: Fulvio Renoldi Bracco
- Chief Financial Officer at Bracco Imaging: Roberto Desimini
- Chief Corporate Development Officer and Head of Strategic Initiatives at Bracco Imaging: Cyrille Petit
- Chief Executive Officer at Equita: Andrea Vismara
- Director of R&D of the Global Business Unit Imaging of Bracco: Fabio Tedoldi
- Number of Employees: No information is available
- Revenue: No information is available
- What is the company known for: Blue Earth Diagnostics is known for its innovative molecular imaging technologies, particularly in the field of PET radiopharmaceuticals for cancer diagnostics.
Products
Axumin® (Fluciclovine F 18)
- Description: A PET imaging agent used for detecting and locating suspected prostate cancer recurrence in men with elevated PSA levels following prior treatment.
- Key Features:
- FDA-approved for PET imaging in men with suspected prostate cancer recurrence.
- Provides images that can inform clinical management decisions regarding prostate cancer treatment.
- Approved for use in both the USA and Europe.
POSLUMA® (Flotufolastat F 18)
- Description: A PET imaging agent targeting PSMA (prostate-specific membrane antigen) for men with suspected prostate cancer recurrence or metastasis.
- Key Features:
- First radiohybrid PSMA-targeted PET imaging agent approved by the FDA.
- Indicates PSMA-positive lesions.
- Useful in both metastatic assessment and recurrent prostate cancer detection.
Research Pipeline
- Fluciclovine(18F)
- Indication: Brain metastases
- Application: PET imaging
- Development Stage: Preclinical
- FAP-targeted Technology
- Indication: Multiple solid tumors
- Application: PET imaging
- Development Stage: Preclinical
Radiopharmaceutical Therapies
- Radiohybrid PSMA (rhPSMA)
- Description: Ongoing investigation for prostate cancer imaging and potential therapeutic applications through the sister company, Blue Earth Therapeutics.
Recent Developments
- May 2023: U.S. FDA grants approval for POSLUMA® (flotufolastat F 18) Injection.
- July 2024: Blue Earth Diagnostics lauds CMS proposal to support patient access through improved payment for specialized diagnostic radiopharmaceuticals.
- July 2024: Marco Campione appointed as Chief Executive Officer.
- May 2024: Agreement with Siemens Healthineers to share PET imaging agent POSLUMA® clinical data to support AI-based algorithms development.
- October 2023: Collaboration with Sinotau Pharmaceutical Group to bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China.
- January 2024: Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and post-scan changes in management in patients with suspected recurrence of prostate cancer at ASCO GU.
This report serves as a comprehensive analysis of Blue Earth Diagnostics, including its mission, history, key personnel, products, and recent noteworthy developments in the molecular imaging market, specifically focused on cancer diagnostics and radiopharmaceuticals.
